Biotech rehearses its ‘difficult’ second album at #JPM16

Damian Garde

The two most commonly watched indexes of stocks have each fallen more than 35% from their July peaks, battered down by a pervasive sense that the frothy days of the boom, when becoming "the Amgen of" anything seemed at least glancingly possible, have passed. And that sentiment permeated this year's J.P. Morgan Healthcare Conference.

FierceBiotech News

Share This Post

Related Articles

Leave a Reply

© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS